A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy
Clinical trial NCT04027309 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04027309
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-20
- Primary completion
- 2025-10-01
- Enrollment
- 777
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.